Morgan Stanley’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-889,505
| Closed | -$16M | – | 6976 |
|
|
2020
Q2 | $16M | Sell |
889,505
-347,848
| -28% | -$4.84M | ﹤0.01% | 1577 |
|
|
2020
Q1 | $8.82M | Buy |
1,237,353
+675,234
| +120% | +$8.43M | ﹤0.01% | 1900 |
|
|
2019
Q4 | $13.4M | Buy |
562,119
+365,057
| +185% | +$10.1M | ﹤0.01% | 2080 |
|
|
2019
Q3 | $5.29M | Sell |
197,062
-273,246
| -58% | -$7.67M | ﹤0.01% | 2825 |
|
|
2019
Q2 | $12.8M | Buy |
470,308
+291,180
| +163% | +$9.13M | ﹤0.01% | 1903 |
|
|
2019
Q1 | $6.21M | Sell |
179,128
-2,183,281
| -92% | -$63M | ﹤0.01% | 2503 |
|
|
2018
Q4 | $46.1M | Buy |
2,362,409
+2,046,772
| +648% | +$42.1M | 0.01% | 852 |
|
|
2018
Q3 | $8.4M | Sell |
315,637
-182,630
| -37% | -$5.96M | ﹤0.01% | 2591 |
|
|
2018
Q2 | $18.8M | Buy |
498,267
+154,292
| +45% | +$5.9M | 0.01% | 1699 |
|
|
2018
Q1 | $11.2M | Buy |
343,975
+34,574
| +11% | +$1.52M | ﹤0.01% | 2238 |
|
|
2017
Q4 | $15.1M | Sell |
309,401
-24,461
| -7% | -$1.24M | ﹤0.01% | 1959 |
|
|
2017
Q3 | $18M | Buy |
333,862
+7,037
| +2% | +$413K | 0.01% | 1683 |
|
|
2017
Q2 | $18.4M | Sell |
326,825
-228,922
| -41% | -$9.17M | 0.01% | 1607 |
|
|
2017
Q1 | $21.8M | Sell |
555,747
-565,215
| -50% | -$18M | 0.01% | 1478 |
|
|
2016
Q4 | $25.2M | Buy |
1,120,962
+866,047
| +340% | +$16.9M | 0.01% | 1339 |
|
|
2016
Q3 | $5.79M | Sell |
254,915
-133,524
| -34% | -$3.13M | ﹤0.01% | 2526 |
|
|
2016
Q2 | $9.17M | Buy |
388,439
+96,505
| +33% | +$2.38M | ﹤0.01% | 2055 |
|
|
2016
Q1 | $5.96M | Buy |
291,934
+56,986
| +24% | +$1.81M | ﹤0.01% | 2362 |
|
|
2015
Q4 | $12.1M | Buy |
234,948
+15,853
| +7% | +$769K | ﹤0.01% | 1802 |
|
|
2015
Q3 | $9.34M | Buy |
219,095
+34,064
| +18% | +$1.64M | ﹤0.01% | 2019 |
|
|
2015
Q2 | $8.43M | Sell |
185,031
-50,539
| -21% | -$2.03M | ﹤0.01% | 2280 |
|
|
2015
Q1 | $8.94M | Buy |
235,570
+122,884
| +109% | +$4.22M | ﹤0.01% | 2170 |
|
|
2014
Q4 | $3.19M | Buy |
112,686
+57,857
| +106% | +$1.61M | ﹤0.01% | 3155 |
|
|
2014
Q3 | $1.39M | Buy |
54,829
+2,422
| +5% | +$63.8K | ﹤0.01% | 3749 |
|
|
2014
Q2 | $1.53M | Sell |
52,407
-87,107
| -62% | -$2.11M | ﹤0.01% | 3706 |
|
|
2014
Q1 | $3.61M | Buy |
139,514
+60,777
| +77% | +$1.62M | ﹤0.01% | 2891 |
|
|
2013
Q4 | $2.03M | Buy |
78,737
+12,982
| +20% | +$315K | ﹤0.01% | 3369 |
|
|
2013
Q3 | $1.76M | Sell |
65,755
-16,792
| -20% | -$400K | ﹤0.01% | 3332 |
|
|
2013
Q2 | $2.03M | Buy |
+82,547
| New | +$1.64M | ﹤0.01% | 3142 |
|
Morgan Stanley's PTLA Position: Q3 2020 in Review
Morgan Stanley sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 889,505 shares — an estimated $16M sold.
Morgan Stanley first reported a position in PTLA in Q2 2013 and held it in 29 quarters. The position peaked at $46.1M in Q4 2018. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- Morgan Stanley reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Morgan Stanley sold 889,505 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $16M.
- Morgan Stanley first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 29 quarters.
- Morgan Stanley's Portola Pharmaceuticals, Inc. position peaked at $46.1M in Q4 2018.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on Morgan Stanley's 13F filing for Q3 2020, filed 13 Nov 2020.